Advanced Enzyme Technologies Ltd (ADVENZYMES) AI Stock Analysis

• Market Cap: ₹35.03B
• Dividend Yield: 1.67%
• Average Volume (3M): 13.78K
• Price to Earnings (P/E): 25.6
• Beta (1Y): 1.18
• Revenue Growth: 5.89%
• EPS Growth: -1.30%
• Country: IN
• Employees: 323
• Sector: Healthcare
• Sector Strength: 45
• Industry: Chemicals - Specialty
• EPS (TTM): 3.60
• Shares Outstanding: 111,926,800
• 10 Day Avg. Volume: 10,375
• 30 Day Avg. Volume: 13,779
• PEG Ratio: -13.34
• Price to Book (P/B): 2.27
• Price to Sales (P/S): 5.07
• P/FCF Ratio: 28.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹348.00
• Price Target Upside: 11.18% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: ₹348.00 ▲(11.18% Upside)

Advanced Enzyme Technologies Ltd scores well in financial performance due to its strong revenue and profit growth, solid margins, and effective leverage management. However, technical analysis indicates bearish momentum and valuation metrics suggest the stock is fairly priced but not a standout in terms of value. The absence of earnings call data and corporate events limits further insights.

Advanced Enzyme Technologies Ltd Business Overview & Revenue Model

Company Description

Advanced Enzyme Technologies Ltd (ADVENZYMES) is a leading global company specializing in the research, development, and manufacturing of enzyme products. Serving a diverse range of sectors including pharmaceuticals, food processing, baking, animal nutrition, and textiles, ADVENZYMES is dedicated to providing innovative enzyme solutions that enhance productivity and sustainability. Its core products include enzymes for digestive health, nutritional supplements, and industrial applications, supporting a broad spectrum of consumer and industrial needs.

How the Company Makes Money

ADVENZYMES makes money primarily through the sale of its enzyme products to various industries such as pharmaceuticals, food and beverage, animal nutrition, and textiles. The company generates revenue by offering tailored enzyme solutions that enhance efficiency, reduce costs, and improve product quality for its clients. Key revenue streams include direct sales to manufacturers and processors, contract manufacturing, and strategic partnerships with industry leaders to co-develop new enzyme applications. The company also invests in research and development to innovate and expand its product portfolio, which in turn drives additional revenues and strengthens its market position. Strategic partnerships and collaborations with global and regional players further augment its earnings by expanding market reach and facilitating entry into new markets.

Advanced Enzyme Technologies Ltd Financial Statement Overview

Summary

Advanced Enzyme Technologies Ltd demonstrates a strong financial position with consistent revenue and profit growth, solid profit margins, and effective leverage management. While the slight decline in EBIT margin and modest free cash flow growth present areas for improvement, the company remains financially sound with minimal risk.

Income Statement

Advanced Enzyme Technologies Ltd shows a strong income statement with consistent revenue growth, evidenced by a 6.8% increase in the latest year. The company maintains high profit margins, with a net profit margin of over 20% and a gross profit margin around 48%. However, the slight decline in EBIT margin suggests efficiency improvements are needed. Overall, the company is financially healthy with robust profitability.

Balance Sheet

The balance sheet indicates a solid financial structure with a low debt-to-equity ratio of 0.03, showcasing strong leverage management. The equity ratio stands at a stable 87.6%, indicating reliance on equity financing. The return on equity is healthy at 9.2%, though slightly lower than industry leaders. Overall, the company displays a stable and conservative balance sheet with minimal financial risk.

Cash Flow

The cash flow statement reflects robust operating cash flows with a steady growth trend. The free cash flow to net income ratio is favorable, indicating efficient cash generation relative to earnings. However, the free cash flow growth rate has been modest. The company manages its capital expenditures prudently, but could enhance free cash flow growth further.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.68B	6.37B	6.23B	5.29B	5.41B	5.00B
Gross Profit	4.54B	3.07B	2.46B	4.09B	4.09B	3.95B
EBITDA	2.35B	2.27B	2.27B	2.09B	1.79B	2.41B
Net Income	1.37B	1.31B	1.33B	1.20B	1.06B	1.46B
Balance Sheet
Total Assets	0.00	16.21B	15.35B	12.68B	14.22B	11.53B
Cash, Cash Equivalents and Short-Term Investments	5.92B	5.88B	5.48B	3.74B	4.86B	3.17B
Total Debt	0.00	393.50M	473.08M	347.30M	334.99M	276.15M
Total Liabilities	-14.69B	1.53B	1.64B	1.27B	1.38B	1.22B
Stockholders Equity	14.69B	14.21B	13.24B	10.89B	12.35B	9.71B
Cash Flow
Free Cash Flow	0.00	1.15B	940.56M	941.15M	1.02B	1.43B
Operating Cash Flow	0.00	1.49B	1.41B	1.22B	1.40B	1.63B
Investing Cash Flow	0.00	-990.44M	-646.49M	-249.12M	-2.98B	-260.33M
Financing Cash Flow	0.00	-692.02M	-507.06M	-273.75M	-257.98M	-263.10M

Advanced Enzyme Technologies Ltd Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 313.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ADVENZYMES, the sentiment is Neutral. The current price of 313 is below the 20-day moving average (MA) of 320.58, below the 50-day MA of 323.22, and above the 200-day MA of 311.48, indicating a neutral trend. The MACD of -6.15 indicates Positive momentum. The RSI at 42.77 is Neutral, neither overbought nor oversold. The STOCH value of 21.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ADVENZYMES.

Advanced Enzyme Technologies Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MOREPENLAB	67 Neutral	₹26.37B	28.24	―	0.42%	2.12%	-25.99%
ADVENZYMES	65 Neutral	₹35.03B	25.58	―	1.67%	5.89%	-1.30%
DCAL	58 Neutral	₹43.55B	41.79	―	―	19.85%	―
GUFICBIO	57 Neutral	₹35.26B	57.00	―	0.03%	2.37%	-30.78%
SEQUENT	54 Neutral	₹51.07B	170.85	―	―	12.33%	439.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%